Powered by
CANTON TWP.—MMS Holdings, the Canton Township-based contract research organization for the pharmaceutical industry, is offering $1 million in free data and related services to qualified pharmaceutical and clinical research companies …
ANN ARBOR—The Ann Arbor cholesterol-lowering drug developer Esperino Therapeutics Inc. (NASDAQ: ESPR) announced the appointment of Alan Fuhrman as a Class III director, with a term expiring at the 2022 …
LANSING–The Michigan Economic Development Corp.’s Pure Michigan Business Connect program is now offering a free, online procurement platform to assist suppliers of critical health and human services across a broad …
ANN ARBOR—Millendo Therapeutics Inc. (Nasdaq: MLND), a pharmaceutical startup focused on developing novel treatments for orphan endocrine diseases, provided a corporate update and reported financial results for the year ended …
CANTON TWP.—MMS Holdings Inc., a Canton Township-based contract research organization (CRO) for the pharmaceutical industry, announced the introduction of its Datacise Integrated Safety Explorer, which will debut at the Pharmaceutical …
ANN ARBOR—Esperion Therapeutics Inc. (Nasdaq: ESPR) announced U.S. Food and Drug Administration approval of Nexlizet, a combination tablet of Esperion’s new non-statin cholesterol reducing drug bempedoic acid and an earlier …
MILAN, Italy—Dipharma Francis S.r.l., a contract development and manufacturing organization for the pharmaceutical industry, announced the completion of the new cGMP Quality Control laboratory and c-GMP kilolab at its Kalamazoo …
ANN ARBOR—Esperion Therapeutics Inc. (NASDAQ:ESPR) announced that the U.S. Food and Drug Administration (FDA) approved Nexletol (bempedoic acid) tablet, an oral, once-daily, non-statin cholesterol-lowering medicine. Nexletol is indicated as an …
ALLENDALE—QST Consultations Ltd. has announced that it has changed its name to Abond CRO Inc., launching the new brand through a new website and participation at participation at the Summit …
ANN ARBOR—Millendo Therapeutics Inc. (Nasdaq: MLND), a biopharmaceutical company primarily focused on developing novel treatments for orphan endocrine diseases, announced that Christophe Arbet-Engels has joined the company as Chief Medical …